Community Screening and Management of Hepatitis B, C and Delta in the Mongolian Population Living in France

Launched by HOSPICES CIVILS DE LYON · Jun 18, 2025

Keywords

ClinConnect Summary

This clinical trial is focused on helping the Mongolian community living in France by checking for three types of viral hepatitis infections—hepatitis B, hepatitis C, and hepatitis D. These infections can quietly damage the liver over time and may lead to serious problems like liver cancer or liver scarring if not found and treated early. Because many people with these infections don’t have obvious symptoms, the study aims to screen individuals to find those who might be affected and then connect them with the care and treatment they need to stay healthy.

To join the study, you need to be of Mongolian background, at least 15 years old, and living in France. People already being treated for hepatitis or under certain legal protections cannot participate. If you take part, you’ll be screened for these infections, and if needed, you’ll be offered support to manage your health. This study is important because it helps improve access to care for a community that may face challenges in getting screened and treated, helping to prevent serious liver diseases down the line.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Mongolian people
• • Over 15 years of age
• • Living in France
• • Majors agree to participate or minors whose parental guardians agree to their child's participation in the study
• Exclusion Criteria:
• • People already followed for viral hepatitis, treated or not treated
• • Persons deprived of their liberty by a judicial or administrative decision
• • Adults subject to a legal protection measure (guardianship, curators)
• • People participate in any interventional research except routine care research (old regulation) and category 2 research that does not interfere with the primary endpoint analysis